Oncologix Tech, Inc.
OCLG · OTC
8/31/2022 | 8/31/2021 | 8/31/2020 | 8/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | 0.00% | 0.00% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.01 | -0.19 | 0.14 | 0.45 |
| Growth | ||||
| Revenue 3-Year CAGR | -16.54% | 2.95% | 171.76% | – |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |